홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Ioversol

HCID 3741
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
8771-40-2
표준 SMILES
O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I
InChIKey
AMDBBAQNWSUWGN-UHFFFAOYSA-N
분자식
C18H24I3N3O9
평균 분자량
807.1 g/mol
단동위원소 질량
806.8647

개요

Ioversol is an amidobenzoic acid.

이름 및 식별자

우선 이름
Ioversol
IUPAC
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
영어명
Ioversol
분자식
C18H24I3N3O9
분자량
807.11

이름 및 동의어

ioversol87771-40-2OptirayMP-328Optiray 320IoversolumOptiray 160Optiray 240Optiray 300Optiray 350DTXSID2045521MP 328
이름 더 보기
LoversolP 530oversolIodofolIodophorolIoversol API
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-N3RIB7X24KN,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamideDTXCID0025521N1,N3-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamideioversoloN1,N3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-(2-hydroxyethyl)acetamido)-2,4,6-triiodobenzene-1,3-dicarboxamideRefChem:57669

데이터베이스 식별자

CAS
8771-40-2、87771-40-2
PubChem CID
3741
DTXSID
DTXSID2045521
ChEMBL
CHEMBL1200614
ChEBI
CHEBI:31717
UNII
N3RIB7X24K
EC Number
618-068-0
Nikkaji
J33.102C

물성

구조 계산 물성

XLogP
-3
극성 표면적
200 Ų
수소 결합 공여자 수
8
수소 결합 수용자 수
9
회전 가능 결합 수
12
무거운 원자 수
33
형식 전하
0
복잡도
623

실험 및 물리화학적 성질

DrugsPharmaceuticals
LogP-2.98
SolubilityWater soluble
Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point180-182°C
Collision Cross Section216.25 Ų [M+H]+

물리화학적 성질

녹는점
180 · 180-182°C
끓는 점
864.9 · 864.9±65.0 °C(Predicted)
밀도
37 · d37 1.371 (c = 320 mgI/ml)
저장 조건
Refrigerator
용해도
DMSO(적게), 메탄올(약간)에 용해됨
산도 계수 (pKa)
11.34 · 11.34±0.46(Predicted)
물리적 상태
고체
색상
흰색에서 황백색까지
주요 응용

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ioversol

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
WGK 3
독성
LD50 in mice, rats, rabbits, dogs (gI/kg): 17, 15, >25, >12 i.v.; in male, female rats (mgI/kg): 1000, >1200 intracisternally (Ralston)
HS 번호
2924296000
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

ATC Code · 3건

V08AB07

V - Various

QV - Various

Protein BindingIoversol does not bind to serum or plasma proteins.
Pharmacodynamics · 1건

The contrast enhancement obtained with ioversol is related to iodine content. Immediately after ioversol is injected, a peak in iodine plasma levels can be detected. However, depending on the organ being imaged, the time to maximum contrast will vary. The time to maximum contrast enhancement will range from the time iodine plasma levels reach their highest concentration to one hour after intravenous bolus administration. The delay between a peak in iodine plasma levels and maximum contrast enhancement is partly due to the accumulation of iodine-containing medium within a lesion and outside the blood pool. For angiographies, the maximum contrast enhancement of ioversol occurs almost immediately (15-120 seconds). Following rapid intravenous injection, ioversol can be visualized in the renal parenchyma within 30 to 60 seconds. In patients with normal renal function, opacification of the calyces and pelves takes place within 1-3 minutes, with an optimum contrast within 5-15 minutes.

Mechanism of Action · 1건

Ioversol is a highly soluble non-ionic ionidated contrast agent. Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, allowing the radiographic visualization of the internal structures until significant hemodilution occurs. In imaging procedures, ioversol diffuses from the vascular to the extravascular space. In brains with an intact blood-brain barrier, this agent does not diffuse to the extravascular space. However, in patients with a disrupted blood-brain barrier, ioversol accumulates in the interstitial space of the disrupted region. As the product Optiray, ioversol enhances computed tomographic imaging through augmentation of radiographic efficiency with the degree of density enhancement directly related to the iodine content in an administered dose.

Biological Half-LifeThe elimination half-life was 1.5 hr in healthy volunteers (n=12) receiving 50 and 150 mL of ioversol 68%. In patients with renal dysfunction, the elimination half-life of ioversol is prolonged.

관련 반응

3건
반응 기록 만들기
HRID 265750 반응식
HRID 265750생성물로
HRID 1358849 반응식
HRID 1358849생성물로
HRID 2395870 반응식
HRID 2395870생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
제약
InChI
InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)
InChIKey
AMDBBAQNWSUWGN-UHFFFAOYSA-N
SMILES
C1(C(NCC(O)CO)=O)=C(I)C(N(C(CO)=O)CCO)=C(I)C(C(NCC(O)CO)=O)=C1I

화학적 성질

White Solid

Metabolism/MetabolitesIoversol does not undergo significant metabolism, deiodination or biotransformation.
FDA Pharmacological Classification · 6건

N3RIB7X24K

IOVERSOL

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Ioversol is a Radiographic Contrast Agent. The mechanism of action of ioversol is as a X-Ray Contrast Activity.

IOVERSOL

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 4건

Healthy volunteers that received 50 and 150 mL of ioversol, had a corresponding Cmax of 1.45 mg/mL and 2.36 mg/mL and a corresponding tmax of 2.0 min and 4.3 min. AUC was 1.74 mg⋅hr/mL in healthy volunteers that received 50 mL of ioversol, and 4.43 mg⋅hr/mL in those that received 150 mL. The pharmacokinetics of ioversol follow an open two compartment model with first-order elimination. Since ioversol is almost completely excreted by the kidney as a parent drug, patients with renal impairment are expected to have a lower elimination rate.

Following intravascular administration, ioversol is excreted mainly through the kidneys. Within the first 24 hours, more than 95% of the administered dose is excreted. Urine concentration peaks in the first 2 hours after ioversol is administered. Fecal elimination is negligible.

In adults, the volume of distribution of ioversol was 0.26 L/kg body weight, consistent with its extracellular space distribution.

In healthy volunteers that received 50 mL of ioversol, clearance was 156 mL/min, and in those receiving 150 mL of ioversol, clearance was 185 mL/min.

용도 및 제조

UsesUse (kg) in Switzerland (2009): >2500
응용 분야 · 3건

용도Nonionic, low osmolality, radiographic contrast agent. Diagnostic aid (radiopaque medium).

용도Loversol is a radiopaque contrast agent. Ioversol contains iodine, a substance that absorbs x-rays. Contrast agents are used to allow blood vessels, organs, and other non-bony tissues to be seen more clearly on a CT scan or other radiologic (x-ray) examination.

일반 설명Ioversol is a low-osmolar, nonionicmonomer with 47% bound iodine content. It is indicated forangiography, excretory urography, ventriculography, andvarious CT procedures.

상·하류 제품 정보

상류 원료

5-[2-chloro-N-(2-hydroxyethyl)acetamido]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamideN-DesMethylIo메프롤5–클로로-아세트아미도-N,N–비스(2,3–디하이드록시프로필)-2,4,6–트리요오도-1.프탈리미도5-[[2-(아세틸옥시)아세틸]아미노]-2,4,6-트리요오도-1,3-벤젠디카르보닐디클로라이드